PHP
Parkman Healthcare Partners Portfolio holdings
AUM
$864M
This Quarter Return
+2.15%
1 Year Return
+33.7%
3 Year Return
+258.24%
5 Year Return
+878.92%
10 Year Return
–
AUM
$843M
AUM Growth
+$843M
(+12%)
Cap. Flow
+$124M
Cap. Flow
% of AUM
14.72%
Top 10 Holdings %
Top 10 Hldgs %
33.86%
Holding
109
New
20
Increased
44
Reduced
26
Closed
18
Top Buys
| 1 |
Zimmer Biomet
ZBH
|
$22.7M |
| 2 |
CVS Health
CVS
|
$21.5M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
$19.6M |
| 4 |
UnitedHealth
UNH
|
$15.8M |
| 5 |
Revvity
RVTY
|
$14.8M |
Top Sells
| 1 |
VRNA
Verona Pharma
VRNA
|
$29.2M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$20.3M |
| 3 |
Abbott
ABT
|
$20M |
| 4 |
Gilead Sciences
GILD
|
$17.5M |
| 5 |
Boston Scientific
BSX
|
$11.2M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Danaher
DHR
$147B
| $13M | 1.54% |
+63,250
| New | +$13M |
|
27
MannKind Corp
MNKD
$1.76B
| $12.5M | 1.49% |
2,493,836
-632,891
| -20% | -$3.18M |
|
28
Ultragenyx Pharmaceutical
RARE
$2.89B
| $11M | 1.31% |
304,244
+204,085
| +204% | +$7.39M |
|
29
Quest Diagnostics
DGX
$20.3B
| $10.6M | 1.26% |
62,593
-27,759
| -31% | -$4.7M |
|
30
Axogen
AXGN
$743M
| $9.93M | 1.18% |
536,832
+171,129
| +47% | +$3.17M |
|
31
Xeris Biopharma Holdings
XERS
$1.28B
| $9.77M | 1.16% |
1,780,454
+1,201,943
| +208% | +$6.6M |
|
32
Arcus Biosciences
RCUS
$1.13B
| $9.54M | 1.13% |
1,215,629
-58,160
| -5% | -$457K |
|
33
Schrodinger
SDGR
$1.41B
| $9.5M | 1.13% |
481,470
-81,621
| -14% | -$1.61M |
|
34
Edgewise Therapeutics
EWTX
$1.57B
| $9.36M | 1.11% |
425,407
+44,234
| +12% | +$973K |
|
35
Replimune Group
REPL
$461M
| $9.27M | 1.1% |
950,399
+80,640
| +9% | +$786K |
|
36
DexCom
DXCM
$29.1B
| $8.9M | 1.06% |
130,367
+51,817
| +66% | +$3.54M |
|
37
KalVista Pharmaceuticals
KALV
$678M
| $8.7M | 1.03% |
+753,752
| New | +$8.7M |
|
38
Day One Biopharmaceuticals
DAWN
$758M
| $8.27M | 0.98% |
1,043,162
+42,688
| +4% | +$339K |
|
39
Nuvalent
NUVL
$5.54B
| $7.8M | 0.93% |
109,988
+86,400
| +366% | +$6.13M |
|
40
BioCryst Pharmaceuticals
BCRX
$1.74B
| $7.5M | 0.89% |
1,000,562
+783,681
| +361% | +$5.88M |
|
41
Syndax Pharmaceuticals
SNDX
$1.39B
| $7.31M | 0.87% |
594,987
+68,014
| +13% | +$836K |
|
42
ANI Pharmaceuticals
ANIP
$2.03B
| $7.03M | 0.83% |
+105,000
| New | +$7.03M |
|
43
Castle Biosciences
CSTL
$696M
| $7.02M | 0.83% |
350,551
+45,922
| +15% | +$919K |
|
44
LivaNova
LIVN
$3.11B
| $6.55M | 0.78% |
166,871
-8,063
| -5% | -$317K |
|
45
QuidelOrtho
QDEL
$1.92B
| $6.42M | 0.76% |
183,678
+8,263
| +5% | +$289K |
|
46
Treace Medical Concepts
TMCI
$453M
| $5.99M | 0.71% |
+713,539
| New | +$5.99M |
|
47
Xenon Pharmaceuticals
XENE
$3.03B
| $5.86M | 0.69% |
174,576
-18,428
| -10% | -$618K |
|
48
Doximity
DOCS
$12.5B
| $5.43M | 0.64% |
+93,500
| New | +$5.43M |
|
49
ResMed
RMD
$40.2B
| $5.06M | 0.6% |
+22,622
| New | +$5.06M |
|
50
Veracyte
VCYT
$2.39B
| $4.93M | 0.58% |
166,278
+65,977
| +66% | +$1.96M |
|